VJHemOnc is committed to improving our service to you

ASH 2019 | PLAT-02 and -05 trials for CAR-T in R/R infant ALL

VJHemOnc is committed to improving our service to you

Colleen Annesley

Colleen Annesley, MD, Seattle Children’s Research Institute, Seattle, WA, discusses two clinical trials, PLAT-02 (NCT02028455) and PLAT-05 (NCT03330691), exploring the use of CAR T-cell immunotherapy for infants with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Results show successful manufacture and administration of a CAR T-cell products in most infant patients, while toxicity and MRD negative complete remission rates were comparable to that of older children or adolescents with ALL. In addition, Dr Annesley reveals that infant patients with R/R ALL are not at increased risk for lineage switch relapse. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter